anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary spontaneous pneumothorax most commonly occurs in young, tall, lean males. The estimated recurrence rate is 23-50% after the first episode and increases to 60% after the second pneumothorax. The pathogenesis of this benign disease remains unclear. Generally, rupture of the emphysematous change or blebs in the apex of the lung is considered as the cause of pneumothorax. The main purpose of this study is to investigate the molecular pathogenesis of blebs formation or emphysematous change of the lung in these young, healthy patients. The blebs resected from the pneumothorax patients will be used for RNA and protein levels analyses. The adjacent normal lung tissue will be used as a control for comparison.
BACKGROUND: Lisfranc injuries are often treated with open reduction and internal fixation using rigid fixation techniques. The use of flexible fixation to stabilize the Lisfranc joint is a newer technique. The purpose of this cadaveric study is to compare the amount of diastasis at the Lisfranc interval under diminished physiologic loads when treated with a knotless suture tape construct and a solid screw.
METHODS: Ten cadavers (20 feet) had native motion at the intact Lisfranc interval assessed at multiple increasing loads (69, 138, and 207 N). The Lisfranc ligamentous complex was then disrupted, and testing repeated to evaluate the amount of diastasis. Randomization was performed to determine the type of fixation for each cadaver: solid screw or knotless suture tape construct. Once fixation was completed, specimens were cyclically loaded for 10 000 cycles at loads, and diastasis was quantified after each load cycle to compare the interventions. Diastasis was measured using motion tracking cameras and retroreflective marker sets. A non-inferiority statistical analysis was performed.
RESULTS: Diastasis mean values were confirmed to be >2 mm for all load bearing conditions in the injury model. Posttreatment, diastasis was significantly reduced when compared to the sectioned conditions (P < .01) for both treatment options. Non-inferiority analyses showed that the knotless suture tape construct did not perform inferior to screw fixation for diastasis at the Lisfranc interval at any of the compared load states.
CONCLUSION: Under the loads tested, there is no significant difference in diastasis at the Lisfranc interval when treating ligamentous Lisfranc injuries with a knotless suture tape construct or solid screws. Both reduced diastasis from the injured state and were not different from the intact state.
CLINICAL RELEVANCE: In this cadaveric model with ligamentous Lisfranc injury, diastasis of a knotless suture tape construct is compared to solid screw fixation as tested.
The invention provides a miRNA marker, which is miRNA550-a 1. The invention utilizes NCBI GEO data to search out 2 sets of osteosarcoma miNRA data sets and 4 sets of osteosarcoma mRNA data sets which meet the requirements, analyzes the data sets and screens miRNA-miRNA 550-a1 which is closely related to osteosarcoma. miRNA550-a1 can be used for judging whether osteosarcoma is transferred or predicting the transfer risk of osteosarcoma. Tests prove that the miRNA550-a1 can effectively distinguish osteosarcoma transfer samples from non-transfer samples. On the basis, the miRNA550-a1 can also be used for preparing medicaments for inhibiting osteosarcoma metastasis or preventing osteosarcoma metastasis. The invention provides a new thought for the molecular mechanism research of osteosarcoma, and simultaneously provides a new diagnosis method for clinically diagnosing osteosarcoma metastasis on a molecular level, and provides a new drug target for osteosarcoma metastasis treatment.
This article presents preliminary findings from a design ethnographic study examining pelvic floor care practices from the perspective of patients with pelvic floor injuries caused by birth treated at the continence clinic in Sundsvall's Hospital, Sweden. The aim is to enhance our understanding of women's experiences of pelvic floor injury, provide insights into living with pelvic floor injury, and discuss this from a universal design perspective. The study combines qualitative observations during clinic meetings and individual interviews with participants in a separate room. In total, seven patients participated. The material was analysed using thematic analysis focusing on the patient's experiences and the continence clinic healthcare meeting situation. The initial findings show that pelvic floor injury symptoms such as leakage, pain and discomfort were seen as a routine part of giving birth and as expected and normal among patients. Another finding is how manifestation through visual evidence with mirroring or illustrations is found to be helpful among patients as it helps them with their healing process. Many participants have unresolved thoughts on the reasons for their pelvic floor injury. The narratives of patients living with pelvic floor injuries highlight themes of ambivalence and uncertainty, with the injuries often overshadowed by the subsequent demands of caring for a newborn, causing overload. The change is not only interpersonal; from a design perspective, the situation as a whole is of interest, including the environment, people, and artefacts. Further research is needed to explore women's experiences beyond the purely medical aspects. Here, universal design can contribute to increased sensitivity regarding stigma and values and how these can manifest socio-materially in healthcare interactions. This study provides a basis for continued work with co-creation workshops with participants in the following study.
PURPOSE:To provide an ointment base having excellent coating and protecting capability, free from stickiness and skin irritation, resistant to the oxidative degradation, and containing orange roughy oil extracted from the subcutaneous fat, skin, head, etc. of orange roughy which is a fish belonging to Trachichithyidae family. CONSTITUTION:The objective ointment base contains (refined) orange roughy oil extracted from the subcutaneous fat, skin, head, etc. of orange roughy (general name of fish including Hoplostethus atlanticus, Hoplostethus mediterraneus, Hoplostethus gilchristi, Hoplostethus intermedius, etc.) which is a fish belonging to Trachichthyidae family. The oil is free of triglyceride structure and resistant to oxidation. It has excellent high-temperature resistance, is applicable smoothly to the skin giving moistened and refreshing feeling with little skin irritation, forms an oily film to the epidermis, and exhibits excellent coating and protecting action and the incarnant action to the skin.
The type of our study was planned as Case-Control. 50 exercises will be included in our study. The first COVID-19 (n= 25) is healthy, and the second group will come from the successful group without COVID-19 (n=25). Between February and April, a student will accept participating in the clinic at Bezmialem Foundation University. After being informed about it, the attached form will be signed. In addition, participants will be asked to fill in our attached document, including demographic and clinical studies, in a face-to-face interview. All body exercises, breathing muscle test, six-minute walking test, McGill core endurance test, short-form test, and quality of life test were planned in our two groups. The results of these tests will be evaluated by testing and checking.
BACKGROUND: Blended mHealth interventions (mHealth interventions including a facilitator) promote user engagement and increase effectiveness of health behavior change interventions. Little is known about how blended mHealth interventions are used outside the research context.
METHODS: In the present work, we characterized patterns of app use among users of a blended mHealth intervention in real-world conditions. Program users were Veterans Health Administration (VHA) primary care patients (n = 56) who received an invite code for a blended mHealth intervention between 2019 and 2021. Cluster analysis was used to examine user engagement with health coach visits and program features.
RESULTS: Of patients who received an invite code, 34% initiated the program. Most users were men (63%) and white (57%). The mean number of health conditions was 5 (68% with obesity). The mean age was 55. Cluster analysis suggested that most users did sustain engagement at either moderate (57%) or very high levels (13%). The remaining 30% of users were low engaged users. Users completing any health coach visit (about half) reported more overall engagement than their counterparts who did not. Weight was the most frequently tracked metric. Of users entering weights in the first and last month of the program (n = 18), the mean percent body weight change was 4.0% (SD = 3.6).
CONCLUSIONS: A blended mHealth intervention may be a scalable option to extend the reach of health behavior change interventions for those that use it. However, a significant portion of users do not initiate these interventions, choose not to use the health coach feature, or engage at lower levels. Future research should examine the role of health coaching visits in promoting sustained engagement.
Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
The invention discloses a traditional Chinese medicine composition for treating snake bite ulcers. The traditional Chinese medicine composition for treating snake bite ulcers is prepared from the following raw materials in parts by weight: 3-6 parts of radix sophorae subporstratae, 15-20 parts of Barbat Skullcap, 8-10 parts of dayflower, 7-9 parts of Herba Lysimachiae, 4-6 parts of radix rehmanniae, 0.5-1.5 parts of moleplant seed, 8-10 parts of ampelopsis root, 3-5 parts of radix rhapontici, 3-5 parts of Herba Patriniae, 2-4 parts of radix astragali and 2-4 parts of licorice root. The invention also discloses a preparation method of the traditional Chinese medicine composition for treating snake bite ulcers. Under the interactions of all the medicines, the traditional Chinese medicine composition is capable of clearing away heat and toxic material, removing dampness by diuresis and relaxing the bowels, and can promote toxins to be quickly discharged, thereby essentially dispelling the toxins. The composition has the effects of reducing the stagnation, promoting the subsidence of swelling, evacuating pus, removing blood stasis with drastic drugs, removing blood stasis, promoting tissue regeneration, alleviating pain, removing necrotic tissues and pus, promoting tissue regeneration and wound healing and relieving ulcer symptoms. The composition is capable of replenishing qi to invigorate the spleen, coordinating the drug actions of the prescription and protecting the liver and the kidney, and can treat both the symptoms and root causes.
All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
FIELD: veterinary science, immunology. SUBSTANCE: vaccine is prepared from avirulent strain of Rockborn distemper virus and avirulent strain Vnukovo-32 rabies virus. Vaccine is prepared in ampoules filled with inert gas. This vaccine - a mixture of two cultured vaccines: live attenuated vaccine against carnivorous plague grown in green monkey kidney tissue primary cells or in monkey kidney transplanted cellular line (4647), and the inactivated antirabies vaccine grown in the primary cellular line of Syrian hamster culture or in cells 4647. Vaccine is used for prophylactic immunization of dogs against rabies and plague. EFFECT: improved method of vaccine preparing.
The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
The educational programme consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months. The multidisciplinary treatment consists of 4, each one every month, consultations of specialties of nutrition, endocinrology and psychology.
A safe and effective treatment for glaucoma for mammalian species comprises the steps of applying insulin and/or insulin like growth factors (IGF-1) to an eye. In addition to the insulin, another therapeutic agent may be applied to enhance the activity of the insulin. The therapeutic agent may be a pharmaceutical agent or a biochemical pharmaceutical agent. The therapeutic agents include prostaglandin analogs, topical beta-adrenergic receptor antagonists-β blockers, Alpha2-adrenergic agonists hair growth therapeutic agents, beta2-agonist action agents, parasympathomimetic miotic agents, carbonic anhydrase inhibitors, and Physostigmine. In another embodiment, a combination of at least two agents are applied to the eye. To enhance the effect of the insulin, uptake facilitators may be used. Additionally, an antibacterial agent may be applied to control bacterial infection.
Participants will be sent baseline questionnaires online through REDCap (Research Electronic Data Capture; see Appendix 1-email templates), a secure web application, and housed on a secure server. Participants will access a unique REDCap survey link via email to complete questionnaire measures after consenting to the study. After completion of the baseline questionnaires, participants will be connected with an I-InTERACT-North therapist for an Introductory Meeting to conduct a baseline elevation session. If participants do not wish to enroll in the full program, post-intervention questionnaires will be administered online through REDCap post step 1. If they wish to proceed to the full program, they will complete the questionnaires after step 2 or 3.
This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
A method for selection of the treatment modality in impaired receptiveness of endometrium in the women of child-bearing age with infertility provides for diagnosing the type of the impairment by examining morphofunctional state of endometrium and the its match to the phase of menstrual cycle on the day of anticipated implantation window, analyzing the impairment of immune and antioxidant reactivity, and diagnosing the metabolic disorders. Depending on the results of examination, the treatment modality is chosen. In addition, hyper- or hypoproduction of CD16+CD56+UNK-cells are assayed. Within the first month of the therapy all the patients are provided with the course of 10 injection of Inflamafertin. Vitamin E per os is prescribed within 3 months on Days 15-26 of the menstrual cycle. Within the 2nd and 3d months of the therapy, Galavit is injected daily at a dose of or is provided in the form of suppositories twice a day on Days 15-25 of the menstrual cycle when hyperproduction of CD16+CD56+UNK-cells is found out. In case of hypoproduction of CD16+CD56+UNK-cells, Galavit is injected daily at a dose of and suppositories of Galavit are used once a day.
Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
The invention provides a chimeric virus RvHBJX of porcine reproductive and respiratory syndrome and an application of the chimeric virus and belongs to the technical field of genetic engineering in virus. The chimeric virus RvHBJX of porcine reproductive and respiratory syndrome provided by the invention is a chimeric virus which comprises a JXwn06 structural protein coding region of a high pathogenicity PRRSV strain by taking a low pathogenicity PRRSV strain HB-1/3.9 as a framework. After the chimeric virus is continuously passed for 80 times in vitro through an MARC-145 cell, the hereditary property of the virus is stable. The adaptability of the virus on a host cell is gradually enhanced along increase of the passage numbers. After the chimeric virus is passed for 60 times (P60) or over 60 times, the animal body is relatively good in safety, and the inoculated virus can provide 100% immune protection for high pathogenicity PRRSV strain and can be used as a vaccine candidate for the porcine reproductive and respiratory syndrome. The chimeric virus for preventing and treating porcine reproductive and respiratory syndrome has a good application prospect.
One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) is produced by multiple cell types and detectable in blood plasma. DBI acts on GABRA (gamma-aminobutyric acid type A receptor) complexes containing GABRG2 (gamma-aminobutyric acid type A receptor, subunit gamma 2) to inhibit macroautophagy/autophagy and hence can be considered as an "autophagy checkpoint". In patients with poor-prognosis anorexia nervosa, as well as in mice developing stress-induced anorexia, circulating DBI levels are reduced. Using a chemical-genetic system that makes it possible to control DBI secretion by hepatocytes, we showed that increasing DBI levels suffices to prevent anorexia induced by chronic restraint stress or chemotherapy with cisplatin, doxorubicin or paclitaxel in mice. At the mechanistic level, DBI administration acts through GABRA outside of the central nervous system and reduces the plasma levels of anorexigenic factors such as GDF15 (growth differentiation factor 15) and LCN2 (lipocalin 2), as well as anorexigenic signaling via the LCN2 receptor MC4R (melanocortin 4 receptor) in the hypothalamus. Accordingly, DBI supplementation stimulates food intake and normalizes whole body weight, body composition and metabolism in mouse models of anorexia. This normalization extends to the liver transcriptome and metabolome. Altogether, it appears that enhancing DBI levels constitutes a promising strategy for combating anorexia.
The invention belongs to the technical field of virology and gene engineering, and particularly relates to construction, vaccine preparation and application of recombinant pseudotype baculovirus expressing rabies virus main immunogenic glycoprotein (RVG). The recombinant pseudotype baculovirus obtained in the invention contains two expression cassettes of not only an insect cell expression cassette in which RVG expression is driven by a PPH promoter and RVG is displayed on a virion envelop surface, but also a mammal cell expression cassette in which high-efficient expression of RVG in mammal cells is driven by a CMV promoter. A rabies vaccine prepared by the recombinant baculovirus has dual properties of subunit vaccines and live viral vector vaccines. After mouse immunization, the rabies vaccine can stimulate the mouse body to generate high-level rabies virus specific ELISA antibodies, neutralizing antibodies, and IFN-gamma, and has potential vaccine application value. The recombinant baculovirus BV-RVG/RVG is preserved in China Center for Type Culture Collection (CCTCC) with a preservation number of CCTCC NO: V201022. The invention also comprises preparation and application of the recombinant baculovirus vaccine.
OBJECTIVE: This cross-sectional study investigated the relationship between metacognition and mood symptoms four years post-stroke and examined fatigue as a potential moderator for this relationship.
METHODS: A number of 143 participants completed a survey that included the Hospital Anxiety and Depression Scale (HADS), the Metacognition Questionnaire-30 (MCQ-30), the Fatigue Severity Scale (FSS), and the modified Rankin Scale (mRS) (functional status) four years after stroke. Multiple regression analyses adjusting for demographic and stroke-specific covariates were performed with anxiety and depression as dependent variables and fatigue as a moderator.
RESULTS: The proportions of participants satisfying the caseness criteria for anxiety and depression were 20% and 19%, respectively, and 35% reported severe fatigue. Analysed separately, all MCQ-30 subscales contributed significantly to anxiety, whereas only three MCQ-30 subscales contributed significantly to depression. In the adjusted analyses, the MCQ-30 subscales 'positive beliefs' (p < 0.05) and 'uncontrollability and danger' (p < 0.001), as well as fatigue (p < 0.001) and functional status at four years (p < 0.05) were significantly associated with anxiety symptoms. Similarly, the MCQ-30 subscales 'cognitive confidence' (p < 0.05) and 'self-consciousness' (p < 0.05), as well as fatigue (p < 0.001), stroke severity at baseline (p < 0.01), and functional status at four years (p < 0.01) were significantly associated with depression symptoms. Fatigue did not significantly moderate the relationship between any MCQ-30 subscale and HADS scores.
CONCLUSION: Maladaptive metacognitions were associated with the mood symptoms of anxiety and depression, independent of fatigue, even after controlling for demographic and stroke-specific factors. Future studies should implement longitudinal designs to determine whether metacognitions precede anxiety or depression after a stroke, and more strongly indicate the potential of metacognitive therapy for improving the mental health of individuals after a stroke.
Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking SINGULAIR. Post-marketing reports with SINGULAIR use include agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some post-marketing reports involving SINGULAIR appear consistent with a drug-induced effect.

Patients and prescribers should be alert for neuropsychiatric events. Patients should be instructed to notify their prescriber if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with SINGULAIR if such events occur [see Adverse Reactions (6.2)].